Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral ONFekafusp alfa in locally advanced cutaneous squamous cell carcinoma after prior systemic treatment
NL-OMON61517Phase 2Not yet recruiting
- Sponsor
- Philogen
- Start
- Apr 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of onfekafusp alfa in cutaneous squamous cell carcinoma (cSCC), sponsored by Philogen. Primary endpoint: Best Overall Response Rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
onfekafusp alfa
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NL-OMON61517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61517.